{"filing":{"accession_number":"0001493152-26-047601","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-15","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm"},"events":[{"id":36146,"run_id":33325,"accession_number":"0001493152-26-047601","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The filing discloses the closing of a material acquisition whereby Vivos acquired an 11% equity interest in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia test in exchange for 12,000 shares of Series C Convertible Preferred Stock valued at $12 million. Item 1.01 references a prior 8-K describing the agreement, and Item 2.01 (incorporated by reference in Item 3.02) confirms this is an acquisition transaction. The press release emphasizes this as a \"transformational event\" expected to add over $10 million to stockholders' equity and provide access to 325,000+ new patients through established distribution channels, making it material to investors.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40460,"accession_number":"0001493152-26-047601","item_number":"1.01","item_title":", there is no material relationship between the Company or any of its affiliates, directors or officers, on the one hand, and","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of a material acquisition whereby Vivos acquired an 11% equity interest in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia test in exchange for 12,000 shares of Series C Convertible Preferred Stock valued at $12 million. Item 1.01 references a prior 8-K describing the agreement, and Item 2.01 (incorporated by reference in Item 3.02) confirms this is an acquisition transaction. The press release emphasizes this as a \"transformational event\" expected to add over $10 million to stockholders' equity and provide access to 325,000+ new patients through established distribution channels, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:50:38.515220+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40460,"accession_number":"0001493152-26-047601","item_number":"1.01","item_title":", there is no material relationship between the Company or any of its affiliates, directors or officers, on the one hand, and","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of a material acquisition whereby Vivos acquired an 11% equity interest in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia test in exchange for 12,000 shares of Series C Convertible Preferred Stock valued at $12 million. Item 1.01 references a prior 8-K describing the agreement, and Item 2.01 (incorporated by reference in Item 3.02) confirms this is an acquisition transaction. The press release emphasizes this as a \"transformational event\" expected to add over $10 million to stockholders' equity and provide access to 325,000+ new patients through established distribution channels, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:50:38.515220+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-10-19"}]}